Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Transcenta Starts China Trials of Osteoporosis Therapy

publication date: Apr 29, 2022

Suzhou Transcenta has dosed the first patient in a China Phase I trial of a novel therapy for osteoporosis. TST002 (blosozumab) is a humanized anti-sclerostin monoclonal antibody aimed at osteoporosis and other bone loss diseases. Its dual mechanism simultaneously stimulates bone formation and inhibits bone absorption to increase bone mineral density and bone strength. In 2019, Transcenta acquired Greater China rights to blosozumab from Eli Lilly in exchange for an upfront payment of cash and Transcenta equity shares, plus milestones and royalty payments. More details....

Stock Symbol: (HK: 06628)

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital